Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, the authors described a 46-year-old woman with severe atopic dermatitis and alopecia areata, who experienced significant improvements in both conditions after treatment with the interleukin-13 blocker tralokinumab, suggesting a potential therapeutic role for targeting type 2 cytokine IL-13 in such cases.

This review discusses approaches to diagnosing and managing cutaneous manifestations of lupus erythematosus and reports no new clinical results.

In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.

In this study, the novel isoprenylcysteine analog SIG-1451 was shown to inhibit pro-inflammatory cytokine release in various cell-based assays relevant to allergic dermatitis, acting on targets such as IL-4 and IL-6 with potential anti-inflammatory benefits.

This study provides evidence-based recommendations for the off-label use of topical vitamin D in treating certain skin conditions, but highlights the need for higher quality studies for further validation.